INMD
InMode Ltd.
INMD offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over INMD overall, supported by stronger modeled upside and stronger fundamentals.
INMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Strong |
INMD's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
INMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9x | $11.06 | -16% |
| Forward | 9.8x | $13.19 | — |
| Current | 11x | $13.19 | — |
| Fair | 15x | $18.29 | +39% |
| Expensive | 35x | $43.04 | +226% |
Historical ranges are pointers, not guarantees.
INMD has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
INMD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Stable | |
| Stable | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect INMD's profitability to weaken, with its earnings and revenue holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over INMD on the outlook, with more favorable earnings and profitability expectations.
INMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.35 | +10% |
| Q2 2026 | $1.23 | -50% |
| Q2 2025 | $2.47 | +42% |
| Q2 2024 | $1.74 | -19% |
| Q1 2024 | $2.11 | +5% |
| Q4 2023 | $2.30 | +21% |
| Q3 2023 | $2.10 | +1.4% |
| Q2 2023 | $2.14 | +6.5% |
| Q1 2023 | $2.01 | +2% |
INMD has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
INMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $95.6M | 0% |
| Q1 2026 | $82M | +5.3% |
| Q4 2025 | $103.9M | +6.1% |
| Q3 2025 | $93.2M | -28% |
| Q2 2025 | $95.6M | +11% |
| Q1 2025 | $77.9M | -3% |
| Q4 2024 | $97.9M | -23% |
| Q4 2024 | $130.2M | +5.8% |
INMD's revenue has slid since its 2023 peak: $96M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 13% | -11 points |
| Q1 2026 | 12% | -7.8 points |
| Q4 2025 | 25% | -3.4 points |
| Q3 2025 | 22% | -15 points |
| Q2 2025 | 24% | +2.8 points |
| Q1 2025 | 20% | -2.5 points |
| Q4 2024 | 28% | -12 points |
| Q4 2024 | 37% | -0.6 points |
INMD has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over INMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
INMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $20.8M | -13% |
| Q1 2026 | $15.2M | +9% |
| Q4 2025 | $24.4M | -24% |
| Q3 2025 | $27M | -21% |
| Q2 2025 | $24M | -43% |
| Q1 2025 | $14M | -42% |
| Q4 2024 | $32.2M | -45% |
| Q4 2024 | $34M | -13% |
INMD's free cash flow has been positive every quarter for seven years: $87M over the past year, down 16% from the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over INMD on cash flow, with more consistent year-over-year improvement.
INMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -7.1% | -4.6M shares |
| 1 year | -6.7% | -4.3M shares |
| 3 years | -31% | -26.3M shares |
| 5 years | -31% | -26.4M shares |
| Available history | -24% | -18.6M shares |
INMD has the edge over UNH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $56.5M |
| Q1 2026 | $31.2M |
| Q4 2025 | $1.9M |
| Q3 2025 | $5.2M |
| Q2 2025 | $28.1M |
| Q1 2025 | $100M |
| Q4 2024 | $119.8M |
| Q4 2024 | $76.6M |
INMD spent $95M buying back its own shares over the past year, down 71% from the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
INMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -4.7x | Net Cash |
| Q1 2026 | -3.8x | Net Cash |
| Q4 2025 | -2.6x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q2 2024 | -0.5x | Net Cash |
| Q1 2024 | -0.6x | Net Cash |
| Q4 2023 | -0.6x | Net Cash |
INMD has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
INMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.2 | Neutral |
| Stochastic | 4.9 | Oversold |
INMD's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
INMD PE vs Healthcare Sector
| Metric | INMD | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 59% below |
| PE % | 35 | 29 | 6 pts above |
INMD has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
INMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.8 | 4.4% below |
| 20 week MA | $14.5 | 9.3% below |
| 50 week MA | $14.3 | 7.8% below |
| 100 week MA | $14.9 | 12% below |
| 200 week MA | $20.3 | 35% below |
INMD is in a downtrend: it's below all five of its weekly moving averages, and 35% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over INMD on trend strength, trading above more of its moving averages.
INMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.5 | $23.8 | +22% |
| 2021 | $23.8 | $72.1 | +203% |
| 2022 | $72.1 | $35.4 | -51% |
| 2023 | $35.4 | $22.2 | -37% |
| 2024 | $22.2 | $17.0 | -23% |
| 2025 | $17.0 | $14.6 | -14% |
| 2026 YTD | $14.6 | $13.2 | -9.8% |
INMD has finished four years in a row lower, and it's down 9.8% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over INMD on returns for 2026, with the stronger performance.